Results
1 -
10 of
50
(Click
here to explore results)
Drug Discovery for Psychiatric Disorders, CHAPTER 3 Monoaminergic Approaches for Treatment of Schizophrenia . David P. Rotella
, 2012
, Pages 35-55
Nuclear Magnetic Resonance: Volume 37, NMR in living systems . M. J. W. Prior
, 2008
, Volume 37
, Pages 327-356
Electrochemical Detection in HPLC: Analysis of Drugs and Poisons, Applications of HPLC-ED in the analysis of drugs . Roger M. Smith, Robert J. Flanagan, David Perrett, Robin Whelpton
, 2005
, Pages 104-210
Phenotypic Drug Discovery, Chapter 10 Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia . E. Leahy, M. Varney, D. Brunner
, 2021
, Pages 175-197
Designing Multi-Target Drugs, Chapter 2 Clinical Need and Rationale for Multi-Target Drugs in Psychiatry . Mohammed Shahid
, 2012
, Pages 14-31
MALDI Mass Spectrometry Imaging: From Fundamentals to Spatial Omics, Chapter 6 Quantitative MSI: A Review of Biomarker and Drug Quantifications Using Mass Spectrometry Imaging . Anahit Campbell, Jonathan Stauber
, 2022
, Pages 105-130
Drug Discovery for Schizophrenia, CHAPTER 8 GSK3 Networks in Schizophrenia . Jivan Khlghatyan, Gohar Fakhfouri, Jean-Martin Beaulieu
, 2015
, Pages 173-201
Drug Discovery for Psychiatric Disorders, CHAPTER 2 The Pathophysiology of Schizophrenia . Armin Szegedi, Michael Egan
, 2012
, Pages 13-34
Drug Discovery for Psychiatric Disorders, CHAPTER 4 Glutamatergic Approaches for the Treatment of Schizophrenia . John A. Morrow, Robert Gilfillan, Stuart A. Neale
, 2012
, Pages 56-98
Biomedical Imaging: The Chemistry of Labels, Probes and Contrast Agents, Chapter 3 Recent Developments in PET and SPECT Radioligands for CNS Imaging . David Alagille, Ronald M. Baldwin, Gilles D. Tamagnan
, 2012
, Pages 49-143